



# CHAD

Number of new cases

**10 185**

Number of deaths


**7 257**

Number of prevalent cases (5-year)

**16 255**


## Statistics at a glance, 2022

	Males	Females	Both sexes
<b>Population</b>	8 694 145	8 719 429	17 413 574
<b>Incidence*</b>			
Number of new cancer cases	5 605	4 580	10 185
Age-standardized incidence rate	147.4	94.4	118.1
Risk of developing cancer before the age of 75 years (cum. risk %)	16.8	9.8	13.1
Top 3 leading cancers (ranked by cases)**	Prostate Liver NHL	Cervix uteri Breast Liver	Prostate Liver Cervix uteri
<b>Mortality*</b>			
Number of cancer deaths	3 937	3 320	7 257
Age-standardized mortality rate	104.4	71.7	86.2
Risk of dying from cancer before the age of 75 years (cum. risk %)	11.9	7.8	9.7
Top 3 leading cancers (ranked by deaths)**	Prostate Liver NHL	Cervix uteri Liver Breast	Liver Prostate Cervix uteri
<b>Prevalence*</b>			
5-year prevalent cases	8 417	7 838	16 255



## Top 5 most frequent cancers\*\*

**Males**




Total: 5 605

Rank	Cancer site	Number of cases	Percent
1st	Prostate	2 582	46.1%
2nd	Liver	966	17.2%
3rd	NHL	300	5.4%
4th	Bladder	212	3.8%
5th	Colorectum	156	2.8%
-	Others	1 389	24.8%

Number of new cases in 2022, males, all ages

**Females**




Total: 4 580

Rank	Cancer site	Number of cases	Percent
1st	Cervix uteri	1 111	24.3%
2nd	Breast	749	16.4%
3rd	Liver	674	14.7%
4th	Thyroid	408	8.9%
5th	Ovary	192	4.2%
-	Others	1 446	31.6%

Number of new cases in 2022, females, all ages

**Both sexes**



Total: 10 185

Rank	Cancer site	Number of cases	Percent
1st	Prostate	2 582	25.4%
2nd	Liver	1 640	16.1%
3rd	Cervix uteri	1 111	10.9%
4th	Breast	749	7.4%
5th	Thyroid	477	4.7%
-	Others	3 626	35.6%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Prostate	2 582	1	25.4	10.6	1 514	2	20.9	6.3	3 429	39.4
Liver	1 640	2	16.1	2.2	1 568	1	21.6	2.2	2 662	15.3
Cervix uteri	1 111	3	10.9	2.5	841	3	11.6	2.0	2 005	23.0
Breast	749	4	7.4	1.4	446	4	6.1	0.88	1 304	15.0
Thyroid	477	5	4.7	0.58	170	8	2.3	0.30	880	5.1
NHL	349	6	3.4	0.22	234	6	3.2	0.17	654	3.8
Bladder	302	7	3.0	0.36	164	9	2.3	0.21	566	3.3
Stomach	264	8	2.6	0.41	243	5	3.3	0.38	445	2.6
Colorectum	228	9	2.2	0.22	178	7	2.5	0.17	363	2.1
Ovary	192	10	1.9	0.29	134	12	1.8	0.22	330	3.8
Kidney	184	11	1.8	0.18	125	13	1.7	0.13	333	1.9
Pancreas	159	12	1.6	0.22	146	11	2.0	0.21	248	1.4
Lung	159	12	1.6	0.21	153	10	2.1	0.21	260	1.5
Lip, oral cavity	155	14	1.5	0.19	118	14	1.6	0.15	271	1.6
Oesophagus	117	15	1.1	0.15	112	15	1.5	0.15	190	1.1
Brain CNS	71	16	0.70	0.08	62	16	0.85	0.08	131	0.75
Leukaemia	64	17	0.63	0.06	53	17	0.73	0.06	102	0.59
Salivary glands	58	18	0.57	0.04	41	18	0.56	0.03	116	0.67
Melanoma	58	18	0.57	0.09	23	22	0.32	0.05	112	0.64
Larynx	56	20	0.55	0.03	29	21	0.40	0.02	84	0.48
Nasopharynx	49	21	0.48	0.15	36	19	0.50	0.11	71	0.41
Corpus uteri	40	22	0.39	0.06	8	29	0.11	0.02	76	0.87
Multiple myeloma	38	23	0.37	0.06	31	20	0.43	0.05	65	0.37
Kaposi sarcoma	33	24	0.32	0.04	21	23	0.29	0.03	49	0.28
Vulva	30	25	0.30	0.06	20	24	0.28	0.04	57	0.65
Hodgkin lymphoma	30	25	0.30	0.01	20	24	0.28	0.01	71	0.41
Testis	21	27	0.21	0.04	12	28	0.17	0.04	44	0.51
Vagina	17	28	0.17	0.05	13	27	0.18	0.04	29	0.33
Mesothelioma	16	29	0.16	0.03	16	26	0.22	0.03	23	0.13
Oropharynx	12	30	0.12	0.00	5	31	0.07	0.00	25	0.14
Hypopharynx	10	31	0.10	0.02	8	29	0.11	0.02	12	0.07
Gallbladder	3	32	0.03	0.00	3	32	0.04	0.00	1	0.01
<b>All cancers</b>	<b>10 185</b>	-	-	<b>13.1</b>	<b>7 257</b>	-	-	<b>9.7</b>	<b>16 255</b>	-
<b>All cancers excl. NMSC</b>	<b>10 141</b>	-	-	<b>13.0</b>	<b>7 248</b>	-	-	<b>9.7</b>	<b>16 166</b>	-

## Data source and methods

### Incidence



**Country-specific data source:** [ {"dt\_list": "N'djamena Cancer Registry" } ]  
**Method:** Most recent rates from a single registry applied to 2022 population

### Mortality

**Country-specific data source:** No data  
**Method:** Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

### Prevalence

Computed using sex-; site- and age-specific incidence to 1-;3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



\* includes non-melanoma skin cancer (NMSC)

\*\* NMSC included in other cancers

Age standardization using world population ([see link](#))

## References

### Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

### Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

